RGNT · Regentis Biomaterials Ltd. · Financials
Market Cap
$13.91M
Shares
7.02M
Volume · Oct 6
33.96K
Avg daily vol (3M)
76.31K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$13.65M
-384.3%
FY2025
Diluted EPS
-$24.16
-1504.7%
FY2025
Operating Cash Flow
-$1.38M
-114.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| $6.64M | $712K | $1.13M | |
| -$6.97M | $932K | -$1.93M | |
| -$6.68M | $3.87M | -$2.2M | |
| $13.65M | -$4.8M | $4.13M | |
| -$13.65M | $4.8M | -$4.13M | |
| USD/shares | -$24.16 | $1.72 | -$24.09 |
| USD/shares | -$24.16 | $1.72 | -$24.09 |
| shares | 566.74K | 2.77M | 173.51K |
| shares | 566.74K | 2.77M | 173.51K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Short-term borrowings | 2025-12-31 | USD 1,197,000 | 20-F/A filed 2026-02-27 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.